Agenus awards Dr. Armen 4,925 shares as salary
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
ARMEN GARO H reported acquisition or exercise transactions in this Form 4 filing.
Agenus Inc. executive and director Dr. Garo H. Armen received 4,925 shares of Common Stock as stock-based salary for the pay period ending June 12, 2026. The shares were valued using the closing price of $3.30 on that date and are fully vested upon issuance under the Amended and Restated Agenus Inc. 2019 Equity Incentive plan. After this grant, Dr. Armen holds 360,892 shares directly, along with additional indirect holdings through IRA accounts and entities referenced in the footnotes.
Insider Trade Summary
Grant/Award: 4,925 shares
Grant/Award
3 txns
Insider
ARMEN GARO H
Role
See Remarks
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,925 | $3.30 | $16K |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Common Stock — 360,892 shares (Direct);
Common Stock — 60,248 shares (Indirect, See Footnote)
Footnotes (4)
- F1. At his request and with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid in stock, in lieu of cash. The amount reported herein represents the net amount of Dr. Armen's salary for the pay period ending June 12th, 2026. Such shares are issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive are fully vested on the date of issuance.
- F2. $3.30 is the closing price of our Common Stock on June 12th, 2026, the last trading day for the payroll date for the pay period ending June 12th, 2026.
- F3. Shares are held in Dr. Armen's IRA accounts.
- F4. Dr. Armen is trustee and has investment authority for the Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock. Dr. Armen is a general partner in Pixie Partners, a General Partnership ("Pixie"), which as of the date of this report owns 5,000 shares of our Common Stock. Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie and disclaims beneficial ownership to the extent of his pecuniary interest therein.
Key Figures
Stock salary grant: 4,925 shares
Grant valuation price: $3.30 per share
Direct holdings after grant: 360,892 shares
+4 more
7 metrics
Stock salary grant
4,925 shares
Common Stock granted as salary for pay period ending June 12, 2026
Grant valuation price
$3.30 per share
Closing price on June 12, 2026 used for stock salary
Direct holdings after grant
360,892 shares
Common Stock directly owned by Dr. Armen after the transaction
IRA holdings
28,950 shares
Common Stock held in Dr. Armen’s IRA accounts as reported
Additional indirect holdings
31,298 shares
Common Stock held indirectly with nature of ownership per footnote
GRAT holdings
23,950 shares
Common Stock held by Garo Armen 2020 2 Year AG GRAT
Pixie Partners holdings
5,000 shares
Common Stock owned by Pixie Partners; Armen has partial pecuniary interest
Key Terms
Equity Incentive, Compensation Committee, IRA accounts, GRAT, +1 more
5 terms
Equity Incentive financial
"issued in accordance with the Amended and Restated Agenus Inc. 2019 Equity Incentive"
Equity incentive is a form of pay that gives employees or executives a stake in the company through stock or the right to buy stock, often granted with conditions that spread out over time. It matters to investors because it aligns workers’ interests with shareholders—encouraging growth and retention—but can also affect share count and profits when new shares are issued, similar to giving team members a slice of the company pie that can grow or dilute others’ slices.
Compensation Committee financial
"with the approval of the Agenus Inc. Compensation Committee, Garo H. Armen's salary is being paid"
A compensation committee is a group within a company's leadership responsible for setting and reviewing how much top executives and employees are paid, including salaries, bonuses, and benefits. It matters to investors because fair and effective pay decisions can influence a company's performance, leadership motivation, and overall governance, helping ensure that the company’s management is aligned with shareholders’ interests.
IRA accounts financial
"Shares are held in Dr. Armen's IRA accounts."
An IRA account is a tax-advantaged personal savings account designed to help people invest for retirement; think of it as a special piggy bank that gives you tax breaks to encourage long-term saving. Different IRA types change when you pay taxes and when you can take money out, so they matter to investors because the choice affects your after-tax returns, portfolio decisions, and the timing of withdrawals during retirement.
GRAT financial
"Garo Armen 2020 2 Year AG GRAT holder of 23,950 shares of our Common Stock."
pecuniary interest financial
"Dr. Armen has a pecuniary interest in only a portion of the shares held by Pixie"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
At what price was Dr. Armen’s Agenus (AGEN) stock-based salary calculated?
Dr. Armen’s stock-based salary was calculated using $3.30 per share, the closing price of Agenus Common Stock on June 12, 2026. This closing price was the last trading day for the relevant payroll date in the reported pay period.
How is Dr. Armen’s salary being paid according to the Agenus (AGEN) filing?
At Dr. Armen’s request and with Compensation Committee approval, his salary is being paid in stock instead of cash. The 4,925 shares reported represent the net amount of salary for the pay period ending June 12, 2026, issued fully vested.
Is Dr. Armen’s Form 4 transaction an open-market purchase of Agenus (AGEN) stock?
No, the transaction is a stock-based salary grant, not an open-market purchase. The Form 4 describes a compensation-related acquisition of 4,925 fully vested shares issued under Agenus’s 2019 Equity Incentive plan in lieu of paying salary in cash.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates